NuVasive, Inc. provided sales guidance for the full year 2023. For the period, the company expects net sales growth of 6%?8% on an as reported and constant currency basis, compared to full year 2022, based on foreign currency rates as of July 31, 2023.
NuVasive, Inc.
Equities
NUVA
US6707041058
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.98% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
+13.95% | 25.02B |